Lijuan Fu
About Lijuan Fu
Lijuan Fu is a Principal Scientist at BridgeBio, specializing in Drug Metabolism and Pharmacokinetics (DMPK). With a PhD in Environmental Toxicology from the University of California, Riverside, she has extensive experience in guiding DMPK lead-optimization and managing research organizations.
Work at BridgeBio
Lijuan Fu has been serving as a Principal Scientist at BridgeBio since 2021. In this role, she collaborates with chemistry and pharmacology teams to guide drug metabolism and pharmacokinetics (DMPK) lead optimization. She plays a crucial role in elucidating pharmacokinetic/pharmacodynamic (PK/PD) relationships, which are vital for understanding drug efficacy and safety. Additionally, she manages Contract Research Organizations (CROs) to design and execute in vitro and in vivo ADME/PK studies. Fu also communicates DMPK results that influence key decisions in the drug development process and is involved in writing, reviewing, and editing preclinical DMPK reports for regulatory submissions.
Education and Expertise
Lijuan Fu holds a PhD Candidate status in Environmental Toxicology from the University of California, Riverside, where she studied from 2009 to 2014. She also earned a Master's degree in Analytical Chemistry from China Agricultural University, completing her studies from 2006 to 2009. Earlier, she obtained a Bachelor's degree in Chemistry from the same university, studying from 2002 to 2006. Her academic background provides her with a solid foundation in chemistry and toxicology, which she applies in her work in drug metabolism and pharmacokinetics.
Background
Before her current position at BridgeBio, Lijuan Fu held several roles in the pharmaceutical and biotechnology sectors. She worked at Arcus Biosciences in various capacities, including Principal Investigator and Senior Scientist/Bioanalytical Lead in DMPK from 2019 to 2021. She also served as an Application Specialist at SCIEX for eight months in 2017 and as a Postdoctoral Fellow at the University of California, Riverside in 2015. Additionally, she worked as a Research Scientist at Covance from 2015 to 2017. This diverse experience has equipped her with extensive knowledge and skills in drug development and analysis.
Achievements
Lijuan Fu has made significant contributions in the field of drug metabolism and pharmacokinetics throughout her career. At BridgeBio, she serves as a subject matter expert in DMPK for nonclinical development, influencing critical go/no-go decisions in drug development processes. Her expertise in managing CROs and executing ADME/PK studies has enhanced the understanding of drug behavior in biological systems. Fu's role in writing and reviewing preclinical DMPK reports for regulatory submissions demonstrates her commitment to ensuring compliance and facilitating the drug approval process.